From bringing global innovation to China to multinational pharmaceutical companies actively seeking innovation within China; from single-asset licensing to co-development and long-term partnerships—what transformations are unfolding in cross-border collaborations for Chinese innovative drugs?
At the 2026 Zhangjiang Pharma Valley Conference and Shanghai International Biopharma Industry Week, Chen Jinglian, Head of Business Excellence & Innovation for Pfizer China, and Ren Feng, Co-CEO and Chief Scientific Officer of Insilico Medicine, joined a live-streamed session to discuss how Chinese innovation is going global, as well as new opportunities and models for cross-border collaboration.
HOST:
Organizing Committee of BioShanghai Week
Organizing Committee of BioShanghai Week
CO-HOSTS:
Shanghai Pharmaceuticals Holding Co., Ltd.
Shanghai State‑owned Capital Investment Co., Ltd.
Shanghai Pharmaceuticals Holding Co., Ltd.
Shanghai State‑owned Capital Investment Co., Ltd.
EXCELLENCE INNOVATION PARTNER:
Shanghai United Imaging Healthcare Co., Ltd.
Shanghai United Imaging Healthcare Co., Ltd.
ORGANIZERS:
Shanghai Zhangjiang Pharma Valley Ecosystem Technology Development Co., Ltd.
Shanghai Yicai Wanxiang Information Technology Co., Ltd.
Shanghai Zhangjiang Pharma Valley Ecosystem Technology Development Co., Ltd.
Shanghai Yicai Wanxiang Information Technology Co., Ltd.
